Department of Medical and Molecular Genetics, Indiana University School of Medicine, 975 West Walnut Street, Indianapolis, IN 46202-5251, USA.
J Mol Neurosci. 2011 Nov;45(3):706-9. doi: 10.1007/s12031-011-9557-8. Epub 2011 May 26.
Frontotemporal dementia (FTD) is an umbrella term for a heterogeneous group of neurodegenerative disorders that are characterized by changes in cognition, language, personality, and social functioning. Approximately 40% of individuals with FTD have a family history of dementia, but less than 10% have a clear autosomal dominant pattern of inheritance. However, establishing a clear mode of inheritance in FTD is complicated by clinical heterogeneity, variable expression, phenocopies, misdiagnosis, early death due to other causes, missing medical records, and lost family histories. Mutations in the microtubule-associated protein tau and progranulin genes have been reported in the majority of hereditary cases, making genetic testing of at-risk individuals possible. The first step in counseling a family with a history of FTD is to take a comprehensive family history with confirmation of any diagnosis in a family member with medical records to the extent possible. If the pedigree analysis suggests an autosomal dominant pattern of inheritance, genetic testing of an affected relative may be offered to the family to determine if a mutation is present. If a mutation is found, relatives interested in pursuing genetic testing should be referred to a genetic counselor familiar with genetic testing for neurodegenerative disorders. Predictive testing of unaffected and at-risk relatives should only be offered in the context of a comprehensive genetic counseling protocol offering pre- and post-test counseling and support. One survey of at-risk individuals in a large family with FTD found that 50% were interested in testing. In one study actually offering genetic testing for FTD, the rate of uptake of testing was only 8.4%. A more recent study estimated the uptake for testing for FTD to be somewhere between 7% and 17% and attributed the low uptake to family resistance to testing. While genetic testing may be appropriate for some families with Alzheimer's disease and FTD, uptake of testing may be expected to be low.
额颞叶痴呆(FTD)是一组异质性神经退行性疾病的总称,其特征是认知、语言、人格和社交功能的改变。大约 40%的 FTD 患者有家族痴呆史,但不到 10%的患者有明确的常染色体显性遗传模式。然而,由于临床异质性、表现变异性、表型模拟、误诊、因其他原因早逝、缺少医疗记录和家族病史丢失,在 FTD 中确定明确的遗传模式变得复杂。微管相关蛋白 tau 和颗粒蛋白基因的突变已在大多数遗传性病例中被报道,这使得对高危个体进行基因检测成为可能。在 FTD 家族中进行咨询的第一步是全面采集家族史,尽可能通过确认有医疗记录的家族成员中的任何诊断来证实。如果系谱分析提示常染色体显性遗传模式,可向受影响的亲属提供基因检测,以确定是否存在突变。如果发现突变,对基因检测感兴趣的亲属应转介给熟悉神经退行性疾病基因检测的遗传咨询师。仅在全面遗传咨询方案的背景下,为未受影响和高危亲属提供预测性检测,该方案提供了检测前和检测后的咨询和支持。一项针对 FTD 大型家族中高危个体的调查发现,50%的人对检测感兴趣。在一项实际提供 FTD 基因检测的研究中,检测的接受率仅为 8.4%。最近的一项研究估计,FTD 检测的接受率在 7%至 17%之间,并将低接受率归因于家庭对检测的抵制。虽然基因检测可能适用于一些阿尔茨海默病和 FTD 家族,但预计检测的接受率会很低。